+1.59 %
-6.86 %
-27.66 %
-43.04 %
-43.91 %
-53.43 %
-62.47 %
-79.27 %
+571.58 %
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Read moreMarket cap
372.17M EUR
Turnover
523.79K EUR
P/E (adj.) (26e)
15.55
EV/EBIT (adj.) (26e)
17.86
P/B (26e)
1.73
EV/S (26e)
3.05
Dividend yield-% (26e)
-
